广济药业
(000952)
| 流通市值：22.46亿 | | | 总市值：22.64亿 |
| 流通股本：3.44亿 | | | 总股本：3.47亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 519,982,780.81 | 422,361,332.62 | 307,177,265.18 | 426,504,702.87 |
| 应收票据及应收账款 | 195,054,538.59 | 187,432,575.45 | 212,676,228.75 | 204,616,559.89 |
| 其中：应收票据 | 28,405,484.63 | 19,158,578.01 | 38,646,556.86 | - |
| 应收账款 | 166,649,053.96 | 168,273,997.44 | 174,029,671.89 | 204,616,559.89 |
| 应收款项融资 | 4,097,632.47 | 5,212,622.85 | 10,514,601.56 | 55,268,125.68 |
| 预付款项 | 42,040,841.88 | 40,663,722.93 | 32,299,476.67 | 35,571,268.61 |
| 其他应收款合计 | 6,607,194.42 | 17,769,100.27 | 6,640,911.72 | 6,672,130.07 |
| 存货 | 354,729,548.45 | 353,527,837.35 | 322,032,072.61 | 365,063,824.57 |
| 其他流动资产 | 20,095,144.11 | 27,711,046.4 | 29,482,906.55 | 60,330,932.98 |
| 流动资产合计 | 1,142,607,680.73 | 1,054,678,237.87 | 920,823,463.04 | 1,154,027,544.67 |
| 非流动资产: | | | | |
| 长期股权投资 | - | - | - | 25,803,259.5 |
| 其他权益工具投资 | 7,280,000 | 7,280,000 | 7,280,000 | 7,280,000 |
| 固定资产 | 1,491,476,468.07 | 1,521,447,007.21 | 1,542,437,816.08 | 1,534,094,647.57 |
| 在建工程 | 33,943,868.51 | 28,975,372.52 | 33,096,209.22 | 92,749,741.42 |
| 使用权资产 | 1,845,841.46 | 2,183,667.27 | 2,183,667.27 | 2,549,204.35 |
| 无形资产 | 236,437,489.24 | 238,029,257.28 | 239,621,025.32 | 208,005,653 |
| 开发支出 | 5,191,398.51 | - | - | - |
| 长期待摊费用 | 10,525,232.22 | 8,474,188.46 | 9,115,021.43 | 9,730,101.51 |
| 递延所得税资产 | 20,116,173.69 | 20,740,042.35 | 20,733,230.44 | 14,082,099.54 |
| 其他非流动资产 | 9,821,422.74 | 11,549,559.67 | 18,288,195.85 | 60,707,448.91 |
| 非流动资产合计 | 1,816,637,894.44 | 1,838,679,094.76 | 1,872,755,165.61 | 1,955,002,155.8 |
| 资产总计 | 2,959,245,575.17 | 2,893,357,332.63 | 2,793,578,628.65 | 3,109,029,700.47 |
| 流动负债: | | | | |
| 短期借款 | 431,332,408.96 | 488,742,529.15 | 344,244,499.36 | 457,865,996.5 |
| 应付票据及应付账款 | 158,562,713.84 | 132,051,482.63 | 121,217,596.21 | 150,302,438.4 |
| 其中：应付票据 | 41,535,807.22 | 27,995,623.07 | 8,345,858.49 | 19,332,858.49 |
| 应付账款 | 117,026,906.62 | 104,055,859.56 | 112,871,737.72 | 130,969,579.91 |
| 合同负债 | 7,260,059.51 | 9,434,264.85 | 5,977,632.26 | 11,857,869.53 |
| 应付职工薪酬 | 22,329,492.57 | 21,950,911.62 | 22,833,793.97 | 23,136,704.69 |
| 应交税费 | 8,471,676.03 | 8,808,634.43 | 11,209,314.45 | 8,934,507.1 |
| 其他应付款合计 | 361,794,027.73 | 137,256,241.36 | 80,524,801.45 | 118,876,689.86 |
| 应付股利 | 3,248,886.9 | 3,248,886.9 | 3,248,886.9 | 3,547,722.9 |
| 一年内到期的非流动负债 | 482,740,891.08 | 318,821,490.5 | 313,968,314.39 | 315,887,285.2 |
| 其他流动负债 | 20,749,379.3 | 16,063,911.71 | 27,538,546.9 | 85,949,222.8 |
| 流动负债合计 | 1,493,240,649.02 | 1,133,129,466.25 | 927,514,498.99 | 1,172,810,714.08 |
| 非流动负债: | | | | |
| 长期借款 | 345,022,255 | 345,560,000 | 393,754,013.88 | 317,715,000 |
| 租赁负债 | 1,387,461.01 | 1,346,746.31 | 1,346,746.3 | 1,821,392.42 |
| 长期应付款 | 115,789,109.53 | 363,850,895.55 | 380,961,084.54 | 385,502,158.49 |
| 递延收益 | 12,125,392.93 | 12,713,513.6 | 13,301,634.27 | 13,928,147.8 |
| 递延所得税负债 | 441,686.37 | 504,400.45 | 504,400.45 | 593,184.33 |
| 非流动负债合计 | 474,765,904.84 | 723,975,555.91 | 789,867,879.44 | 719,559,883.04 |
| 负债合计 | 1,968,006,553.86 | 1,857,105,022.16 | 1,717,382,378.43 | 1,892,370,597.12 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 346,750,339 | 349,855,339 | 349,855,339 | 349,855,339 |
| 资本公积 | 365,419,274 | 377,122,996.1 | 377,122,996.1 | 375,183,679.82 |
| 减:库存股 | 9,893,247 | 21,232,116 | 21,232,116 | 21,232,116 |
| 其他综合收益 | -17,760.72 | -17,946.16 | -18,028.9 | -12,385.08 |
| 专项储备 | 1,717,812.59 | 1,155,657.51 | 946,761.22 | 542,094.2 |
| 盈余公积 | 150,873,094.71 | 150,873,094.71 | 150,873,094.71 | 150,873,094.71 |
| 未分配利润 | 131,876,878.74 | 171,125,782.84 | 207,391,941.18 | 344,327,598.22 |
| 归属于母公司股东权益合计 | 986,726,391.32 | 1,028,882,808 | 1,064,939,987.31 | 1,199,537,304.87 |
| 少数股东权益 | 4,512,629.99 | 7,369,502.47 | 11,256,262.91 | 17,121,798.48 |
| 股东权益合计 | 991,239,021.31 | 1,036,252,310.47 | 1,076,196,250.22 | 1,216,659,103.35 |
| 负债和股东权益合计 | 2,959,245,575.17 | 2,893,357,332.63 | 2,793,578,628.65 | 3,109,029,700.47 |
| 公告日期 | 2025-08-29 | 2025-04-28 | 2025-04-28 | 2024-10-31 |
| 审计意见(境内) | | | 带强调事项段的无保留意见 | |